A detailed history of Baillie Gifford & CO transactions in Cellectis S.A. stock. As of the latest transaction made, Baillie Gifford & CO holds 693,939 shares of CLLS stock, worth $1.09 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
693,939
Previous 707,630 1.93%
Holding current value
$1.09 Million
Previous $1.32 Million 11.19%
% of portfolio
0.0%
Previous 0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 05, 2024

SELL
$1.9 - $2.4 $26,012 - $32,858
-13,691 Reduced 1.93%
693,939 $1.47 Million
Q2 2024

Jul 25, 2024

SELL
$1.86 - $3.35 $222,489 - $400,720
-119,618 Reduced 14.46%
707,630 $1.32 Million
Q1 2024

May 01, 2024

BUY
$2.41 - $3.09 $25,558 - $32,769
10,605 Added 1.3%
827,248 $2.19 Million
Q4 2023

Jan 26, 2024

SELL
$0.97 - $3.55 $336,945 - $1.23 Million
-347,366 Reduced 29.84%
816,643 $2.52 Million
Q3 2023

Nov 13, 2023

SELL
$1.58 - $2.86 $402,879 - $729,262
-254,987 Reduced 17.97%
1,164,009 $1.84 Million
Q2 2023

Jul 28, 2023

SELL
$1.72 - $2.12 $379,948 - $468,308
-220,900 Reduced 13.47%
1,418,996 $2.8 Million
Q1 2023

May 03, 2023

BUY
$1.83 - $3.84 $1.9 Million - $3.99 Million
1,040,000 Added 173.36%
1,639,896 $3.16 Million
Q4 2022

Jan 24, 2023

SELL
$1.85 - $2.6 $349,540 - $491,246
-188,941 Reduced 23.95%
599,896 $1.26 Million
Q3 2022

Oct 27, 2022

SELL
$2.29 - $4.08 $210,897 - $375,747
-92,095 Reduced 10.45%
788,837 $1.81 Million
Q2 2022

Aug 08, 2022

SELL
$2.39 - $4.93 $480,779 - $991,733
-201,163 Reduced 18.59%
880,932 $2.49 Million
Q1 2022

May 05, 2022

BUY
$3.45 - $8.77 $8,914 - $22,661
2,584 Added 0.24%
1,082,095 $4.91 Million
Q4 2021

Jan 20, 2022

BUY
$8.01 - $12.84 $23,917 - $38,340
2,986 Added 0.28%
1,079,511 $8.77 Million
Q3 2021

Oct 19, 2021

BUY
$11.94 - $16.09 $509,276 - $686,286
42,653 Added 4.13%
1,076,525 $13.6 Million
Q2 2021

Aug 02, 2021

BUY
$14.36 - $20.93 $14.8 Million - $21.6 Million
1,033,872 New
1,033,872 $16 Million

Others Institutions Holding CLLS

About Cellectis S.A.


  • Ticker CLLS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 45,510,800
  • Market Cap $71.5M
  • Description
  • Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatm...
More about CLLS
Track This Portfolio

Track Baillie Gifford & CO Portfolio

Follow Baillie Gifford & CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Baillie Gifford & CO, based on Form 13F filings with the SEC.

News

Stay updated on Baillie Gifford & CO with notifications on news.